EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis

Arne Strotmann, Theo Leitner, Paolo Mazzeo, Georg Evers, Alexander Pohlmann, Christine Eisfeld, Maximilian Seib, Nikolas von Bubnoff, Georg Lenz, Evgenii Shumilov, Cyrus Khandanpour

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.12.008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Arne Strotmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Melphalan, Hematopoietic Stem Cell Transplantation, Consolidation Chemotherapy. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: High-dose chemotherapy with melphalan (HDCT) and autologous stem cell transplantation (ASCT) represents a gold standard treatment for younger multiple myeloma (MM) patients (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaMelphalanHematopoietic Stem Cell TransplantationConsolidation ChemotherapyHumansRetrospective StudiesFemaleTransplantation, AutologousAgedMaleMiddle AgedAdultAge FactorsTreatment OutcomeAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Elderly patientsHigh-dose chemotherapyOverall survivalPlasma cell neoplasmProgression-free survival

Substanzen

Melphalan

Autor:innen und Institutionen

  • Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.
  • Department for Hematology and Oncology, University Hospital Schleswig-Holstein, University Cancer Center Schleswig-Holstein and University of Luebeck, Luebeck, Germany.
  • Department of Hematology and Medical Oncology, INDIGHO laboratory, University Medical Center Goettingen (UMG), Goettingen, Germany.
  • Department of Medicine A for Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany. Electronic address: evgenii.shumilov@ukmuenster.de.
  • Department for Hematology and Oncology, University Hospital Schleswig-Holstein, University Cancer Center Schleswig-Holstein and University of Luebeck, Luebeck, Germany. Electronic address: cyrus.khandanpour@uksh.de.

Zitieren

APA

Strotmann, A., Leitner, T., Mazzeo, P., Evers, G., Pohlmann, A., Eisfeld, C., Seib, M., von Bubnoff, N., Lenz, G., Shumilov, E., & Khandanpour, C. (2025). Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.008

Vancouver

Strotmann A, Leitner T, Mazzeo P, Evers G, Pohlmann A, Eisfeld C, et al. Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.12.008

BibTeX
@article{Strotmann2025,
  author = {Strotmann, Arne and Leitner, Theo and Mazzeo, Paolo and Evers, Georg and Pohlmann, Alexander and Eisfeld, Christine and Seib, Maximilian and von Bubnoff, Nikolas and Lenz, Georg and Shumilov, Evgenii and Khandanpour, Cyrus},
  title = {Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.12.008}
}
Kostenlos starten →